Synergistic Effect of the Combination of Ranolazine and Dronedarone to Suppress Atrial Fibrillation
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
- National Institutes of Health (HL-47678)
- New York State and Florida Grand Lodges of Free and Accepted Masons
- Gilead Sciences
- AstraZeneca
- Merck
- Cardiome
This publication has 29 references indexed in Scilit:
- New developments in atrial antiarrhythmic drug therapyNature Reviews Cardiology, 2010
- Synergistic Electrophysiologic and Antiarrhythmic Effects of the Combination of Ranolazine and Chronic Amiodarone in Canine AtriaCirculation: Arrhythmia and Electrophysiology, 2010
- Potent Antiarrhythmic Effects of Chronic Amiodarone in Canine Pulmonary Vein Sleeve PreparationsJournal of Cardiovascular Electrophysiology, 2009
- Atrial-selective sodium channel block for the treatment of atrial fibrillationExpert Opinion on Emerging Drugs, 2009
- Atrial-selective effects of chronic amiodarone in the management of atrial fibrillationHeart Rhythm, 2008
- Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparationsHeart Rhythm, 2008
- Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial FibrillationCirculation, 2007
- Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or FlutterNew England Journal of Medicine, 2007
- Late‐Phase 3 EAD. A Unique Mechanism Contributing to Initiation of Atrial FibrillationPacing and Clinical Electrophysiology, 2006
- Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodaroneBritish Journal of Pharmacology, 2001